Natus Medical Announces Exercise of IPO Over-Allotment Option

Business Wire, August 24, 2001

Business Editors & Health/Medical Writers

SAN CARLOS, Calif.--(BW HealthWire)--Aug. 24, 2001

Natus Medical Inc. ("Natus") (Nasdaq:BABY) today announced that the underwriters of its initial public offering, led by Dain Rauscher Wessels, First Union Securities and Adams, Harkness & Hill, have exercised in full the over-allotment option to purchase 750,000 additional shares of the company's common stock.

Natus granted this option in connection with its initial public offering. The closing with respect to the option shares took place on Aug. 17, 2001.

On July 25, 2001, Natus completed an initial public offering of 5,000,000 shares of its common stock at $11 per share. The shares were offered through underwriters led by Dain Rauscher Wessels, First Union Securities and Adams, Harkness & Hill.

About Natus Medical Inc.

Natus Medical develops, manufactures and markets proprietary, non-invasive, easy-to-use, crib-side screening devices for the detection and/or monitoring of common disorders in babies. Natus is a market leader in sales of Newborn Hearing Screening equipment. Natus also manufactures and distributes MiniMuffs(R) Neonatal Noise Attenuators and the CO-Stat(R) End Tidal Breath Analyzer, a technology that non-invasively detects the rate of hemolysis in newborns.

Natus sells and supports its products domestically through direct field sales representatives and clinical educators. Natus products are distributed by its wholly owned subsidiaries in Japan and in the United Kingdom, and have been distributed in 20 other countries. Additional information can be found at www.natus.com.